J & J unit ends hepatitis C drug development in crowded market

(Reuters) - Janssen Sciences Ireland UC, a unit of Johnson& Johnson, said it would discontinue further development of its hepatitis C research, citing increased availability of a number of effective hepatitis C therapies.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news